Photo courtesy of Brainlab
December 22, 2014 — Brainlab announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two software modules for radiation oncologists and neurosurgeons — Adaptive Hybrid Surgery and Automatic Brain Metastases Planning — to round out the Brainlab portfolio.
Adaptive Hybrid Surgery helps physicians balance surgical risk with radiosurgical toxicity for multidisciplinary treatment of skull-base tumors. A complete set of automated tools enables analysis of adjuvant radiosurgery at any time while planning and performing a surgical resection. Elements Intraoperative Structure Update captures residual tumor volumes based on points acquired inside the resection cavity. An intuitive traffic light display provides comprehensive information about tumor coverage and critical dose constraints for calculated treatment plans.
Automatic Brain Metastasis Planning software introduces technology that consistently and rapidly generates radiosurgery plans for the efficient treatment of multiple metastases. This allows clinicians to plan and treat multiple brain metastases with time and dose efficiencies while helping to minimize exposure to healthy surrounding tissue. Treatment delivery and planning time can be reduced drastically, even for as many as 10 metastatic tumors in the brain.
For more information: www.brainlab.com
April 25, 2024 
